Literature DB >> 6753577

Superinfection: another look.

P Sen, R Kapila, H Chmel, D A Armstrong, D B Louria.   

Abstract

Superinfection in the compromised host often poses a diagnostic and therapeutic dilemma for the physician who is concerned that a perplexing array of microorganisms might be involved. We believe that the differential diagnosis list can often be narrowed considerably by separating superinfection in the compromised host into five convenient categories: (1) infections due to the underlying disease itself; (2) infections due to the underlying disease plus therapy for that disease; (3) infections due solely to medicaments, operations, or procedures; (4) infections increased in severity but probably not in incidence; and (5) societally related infections. Use of this or a similar categorization should result in a more rational approach to differential diagnosis, should encourage a more focused diagnostic work-up, whould reduce the necessity for invasive procedures, should provide the microbiology laboratory information about specific organisms that should be sought sedulously, and should permit the selection of a more rational antimicrobial regimen prior to the availability of definitive microbiologic information.

Mesh:

Year:  1982        PMID: 6753577     DOI: 10.1016/0002-9343(82)90414-4

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  3 in total

1.  Clinicopathological patterns of invasive and superficial fungal infection.

Authors:  G S McDonald; P Crowe
Journal:  Ir J Med Sci       Date:  1988-06       Impact factor: 1.568

2.  Invasive aspergillosis of the nose and paranasal sinuses in immunocompromised children.

Authors:  C Rotstein
Journal:  CMAJ       Date:  1988-08-15       Impact factor: 8.262

Review 3.  Root Causes of Fungal Coinfections in COVID-19 Infected Patients.

Authors:  Arman Amin; Artin Vartanian; Nicole Poladian; Alexander Voloshko; Aram Yegiazaryan; Abdul Latif Al-Kassir; Vishwanath Venketaraman
Journal:  Infect Dis Rep       Date:  2021-12-04
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.